Studies of adenovirus EIA oncoprotein mutants suggest that the association of ElA with the retinoblastoma protein (pRB) is necessary for ElA-mediated transformation. Mutational analysis of ELA indicates that two regions of pRB are required for ELA to form stable complexes with the retinoblastoma protein. In addition to pRB binding, these regions are necessary for ElA association with several other cellular proteins, including p130, p107, cycin A, and p33cdk2. Here we show that short synthetic peptides containing the pRB-binding sequences of E1A are sufficient for interaction with p107, cyclin A, and p130. The E7 protein of human papillomavirus type 16 contains an element that binds to pRB and appears to be functionally homologous to the ElA sequences. Peptides containing this region of the E7 protein were able to interact with p107, cyclin A, and p130 in addition to pRB. These findings suggest that the common mechanism of transformation used by these viral oncogenes involves their association with a set of polypeptides.
The adenovirus ElA oncoprotein has pleiotropic effects on cell proliferation. These changes appear to be mediated, at least in part, by the association of ElA with several cellular proteins. Stable protein complexes are readily detected in adenovirus-infected or -transformed cells (29, 58) , and several genetic studies have correlated the ability of ElA mutants to bind to cellular proteins with their activities in transformation assays, cell immortalization, or the stimulation of host cell DNA synthesis after viral infection (19, 33, 36, 53, 57) . To date the binding sites of six cellular proteins have been mapped to the region of ElA with transforming activity. These are the retinoblastoma protein, pRB, and a related protein, p107 (22, 56) ; cyclin A and a cyclin A-associated kinase, p33cdIa (24) (25) (26) 55) ; and two additional proteins, p130 and p300 (26, 57) . Analysis of the protein-binding properties of various ElA mutants has identified short segments of ElA that are essential for stable association with several of these cellular proteins. Deletion of amino acids 120 to 127 largely inhibits the formation of ElA complexes with at least five polypeptides, pRB, p107, p130, cyclin A, and p33Cdk2 (25, 26, 57) . Similarly, ElA deletions that include amino acids 30 to 60 produce ElA mutants that have severely impaired binding to pRB, p130, cyclin A, and p33cdk2 (25, 26, 57) . The binding site of p300 appears to be distinct from that of these other proteins (57) ; it lies within the amino-terminal 49 amino acids of ElA (42) .
The early proteins of other small DNA tumor viruses also bind to pRB (11, 14, 17, 46) . For the large T antigens of simian virus 40 (SV40) and polyomavirus and the E7 proteins of human papillomavirus type 16 , mutagenesis of the pRB-binding sequences reveals a correlation between the pRB-binding properties and the cell immortalization or transforming properties of these oncoproteins (11, 30, 41, (46) (47) (48) . The similarities between these viral proteins suggests that these oncogenes may be using common mechanisms for * Corresponding author. their effects on cell proliferation. This common mechanism may also include association with the pRB-related protein p107, since it shares overlapping binding sites with pRB on ElA and also on the large T antigen of SV40 (15, 23) .
Studies of ElA mutants have pinpointed regions of ElA that are important for protein binding. However, these studies share the limitations of any deletion-mapping strategy. In a deletion mutagenesis, only mutants that retain function can be interpreted, and as a result only the sequences that are essential for binding are revealed. If additional regions of ElA also contribute to the stability of its protein complexes but are not essential for the interaction, they may have been missed by the mutagenesis strategy. As a result, the small regions that are essential for binding to cellular proteins may not be sufficient for the interaction. A further limitation of the deletion-mapping approach is that it cannot distinguish between elements that determine protein conformation and those that are true binding sites. For example, deletion mutants showed that two regions of ElA are essential for its association with pRB, p130, cyclin A, and p33cdk2, but the respective contributions of these regions were not clear.
In order to investigate further the roles of these regions in the association of ElA with pRB and other cellular proteins, we have assayed the protein-binding properties of short synthetic peptides that contain and represent these sequences. It has been shown that small peptides bearing regions of adenovirus type 5 ElA, HPV-16 E7, and SV40 large T antigen are able to inhibit the association between viral proteins and pRB (12, 16, 37, 39, 50 Peptides were bound to cyanogen bromide-activated Sepharose 4B beads through a single terminal amino group as described previously (16) . Peptide-coupling efficiency was monitored by measuring the A205, and routine coupling efficiencies of 80 to 90% were obtained for each peptide.
Peptide competition of ElA complexes formed in vitro. ML-1, HeLa, and 293 cell lines were lysed in 250 mM NaCl-50 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES; pH 7.5)-0.1% Nonidet P-40 as previously described. (54) . Proteins were detected by using monoclonal antibodies to pRB (XZ77 [34] ), cyclin A (C160 [27] ), and p107 (XZ37 [34] ), followed by incubation with alkaline phosphatase-conjugated rabbit antimouse antibody (Bethesda Research Laboratories, Inc.).
Assays measuring binding to peptide beads by pRB polypeptides synthesized by in vitro transcription and translation of the human cDNA clone were carried out as described previously (16) .
Partial proteolytic mapping. V8 partial proteolysis was carried out by using the procedure described by Cleveland et al. (10) . Slices containing the appropriate proteins were excised from a 6% gel and digested with S. aureus V8 protease. Digested proteins were separated on an SDS-15% polyacrylamide gel (40) and visualized by fluorography (4).
Immunoprecipitation and Western blotting analysis. The HFK1321 and HFK40 cell lines were described previously (45, 49) and were obtained by immortalization of primary human foreskin keratinocytes either with the HPV-16 E6/E7 genes expressed from the human 1-actin promoter or with SV40. E7 immunoprecipitations were performed with a monoclonal antibody from Triton Diagnostics (no. 10021) as described previously (48) . pRB was detected after Western immunoblotting by anti-pRB monoclonal antibody PMG3-245.11 (Pharmingen) followed by 1"I-labeled sheep antimouse antibody (Amersham) as previously described (51) .
RESULTS
Synthetic peptides were used to examine the interactions between ElA and cellular proteins. The goals of these studies were twofold: first, to determine whether the small regions of ElA that contain its pRB-binding sites were also sufficient for stable binding to other cellular proteins that are putative targets for ElA-mediated transformation, and second, to determine whether the pRB-binding domain of the HPV-16 E7 protein interacts with the same set of cellular proteins.
Two small regions of ElA that contain pRB-binding sequences were synthesized as peptides and were assayed for binding to ElA-associated proteins. These peptides were used in two types of assay: competition assays and proteinbinding assays. In the first type, synthetic peptides were added as competitors to in vitro binding reactions between ElA and cellular proteins. In the second type, peptides were coupled to beads and then assayed for specific immobilization of ElA-associated proteins. These two assays were used since each approach complements the limitations of the other. Potential pitfalls of peptide competition assays include the possibility that competition results from nonspecific interactions and the possibility that competition does not reflect true contact sites. By immobilizing the peptide on beads and incubating the peptide in a labeled cell lysate, we sought to determine the specificity of the peptide interaction. Furthermore, a positive result in this type of assay demonstrates that the peptide sequences are sufficient for formation of stable complexes and must therefore contain a contact site. We note that neither of these approaches nor the mutagenesis of ElA can distinguish proteins that are directly bound to ElA from those that are indirectly associated. ElA peptides inhibit ElA association with pRB, p107, and p130 polypeptides. Many of the cellular proteins that bind to ElA in vivo form similar complexes with ElA in vitro. This is illustrated in Fig. 1A . Cell lysates prepared from HeLa cells metabolically labeled with [35S]methionine were mixed with unlabeled cell extracts containing ElA (prepared from unlabeled 293 cells). After incubation, radiolabeled proteins that became bound to ElA were immunoprecipitated with an ElA-specific monoclonal antibody. This assay has been described in detail before (15, 29) , and ElA-associated proteins that are readily detected are p300, pRB, p107, and p60. The identities of these proteins have been determined by comparisons of partial proteolytic digestion patterns.
We investigated the effects of adding synthetic peptides that represented small regions of ElA on the in vitro association of ElA with cellular proteins. Initially three peptides were tested. Two of these were peptides that contained the individual pRB-binding sites of ElA: a region 1 peptide (containing amino acids 37 to 54) and a region 2 peptide (containing amino acids 115 to 132). In addition, a peptide that linked sequences from both regions (region 1+2 peptide) through a glutamine (ElA;37-49-Q-117-132) was assayed. None of these peptides affected ElA association with p300. However, ElA binding to pRB and p107 was reduced in the presence of either the region 2 peptide or the region 1+2 peptide, but differences in the degrees of competition were apparent. In this experiment, no competition was seen when the region 1 peptide was used. In other experiments, high concentrations of this peptide marginally reduced ElA association with all of the major proteins (data not shown).
To quantitate the differences between the region 2 peptide and the region 1+2 peptide, we titrated these two competitor peptides into the binding reaction (Fig. 1B) E1A peptides coupled to beads act as efficient and specific adsorbents for cellular proteins including pRB, p107, and p60. To determine whether these small regions of ElA are sufficient for stable interaction and whether the peptides are binding specifically to ElA-associated proteins, we coupled the peptides to Sepharose beads and incubated them in cell lysates. Peptides immobilized in this way have previously been shown to bind efficiently to pRB produced by in vitro translation of the human cDNA clone (16) . Initially the region 1+2 peptide (ElA;37-49-Q-117-132) was used since it was the most potent competitor peptide. This peptide was coupled to beads and incubated in cell lysate prepared from ML-1 cells that were metabolically labeled with [ S]methionine. Very few proteins bound to the beads (Fig. 3) , and their association was inhibited by incubation with uncoupled peptide but not with control peptide. Since the peptide bead-associated proteins comigrated with authentic E1A-associated proteins, it appeared that the binding properties of the peptides were highly specific. We wished to be certain that these proteins were the same proteins that associate with ElA in vivo, and we therefore tested the identities of three of these proteins by partial proteolytic mapping and on Western blots probed with specific monoclonal antibodies. Figure 4 shows a comparison of the products of partial proteolytic digestion of bead-associated proteins with the ElA-associated pRB and p107 proteins; the products of partial digestion with S. aureus V8 protease generated from bead-associated proteins gave patterns identical to those generated from authentic pRB and p107.
Western blots of proteins from ML-1 cell lysate that bound to ElA peptide beads are shown in Fig. 5 . Nitrocellulose strips were probed separately with the anti-pRB monoclonal antibodies XZ77 and XZ37 and with C160, a monoclonal antibody that recognizes human cyclin A. XZ77 is an antipRB monoclonal antibody that cross-reacts weakly with the ElA-associated protein p300 (34) . XZ37 is from the same series of RB antibodies but recognizes an epitope that is also found on p107. As shown in Fig. 5 polyacrylamide gel and transferred to nitrocellulose. pRB, p107, and cyclin A were detected by using the monoclonal antibodies XZ77, XZ37 (34) , and C160 (27) as indicated. 1+2 peptide. A lower level of p107 was also associated with beads carrying region 1 peptides or region 2 peptide but not with beads coupled with control peptide. The pattern of cyclin A binding seen after probing with C160 closely resembled that of p107 binding. These results show that two regions of EMA, when assayed separately, are sufficient for association with p107 and cyclin A. When taken together, the results of competition experiments and binding experiments indicate that the small regions of ElA that contain the binding sites for pRB are also sufficient for interaction with at least three other proteins: p107, p130, and cyclin A.
E7 peptides capable of binding to several ElA-associated proteins. Other oncoproteins of small DNA tumor viruses also contain pRB-binding sequences that are homologous to regions 1 and 2 of ElA. One of the best-studied examples is the E7 protein of HPV-16. Sequences near the amino terminus of E7 have been shown to be essential both for the association with pRB and for E7 transformation activity (3, 18, 30, 46, 48) . Since the pRB-binding regions of ElA mediate association with several proteins, we wished to determine whether E7 sequences had the same properties. Initially we looked for evidence of E7 association with p107 and cyclin A. Immunoprecipitations prepared with anti-E7 antibodies were transferred to nitrocellulose and probed with antibodies that recognize p107, cyclin A, or pRB. pRB was detected in anti-E7 immunoprecipitations prepared from a human keratinocyte cell line immortalized by HPV E6/E7 (HFK1321) but not from a control keratinocyte cell line immortalized by SV40 (HFK40) nor in immunoprecipitations with control antibodies (Fig. 6) . The E7 protein preferentially associated with the faster-migrating forms of pRB, although a lower level of slower-migrating, phosphorylated pRB was also seen bound to E7. This observation of complexes formed in vivo is consistent with results of in vitro binding studies that reported that E7 protein binds preferentially to underphosphorylated pRB (35) . Antibodies to p107 or cyclin A failed to reveal either of these proteins in E7 immunoprecipitations. However, neither of these antibodies are high-affinity reagents, and since the pRB association was barely detectable with better antibodies, it is probable that the detection of E7-associated p107 and cyclin A was beyond the limits of the sensitivity of the experimental system. We therefore tested synthetic peptides containing the pRB-binding sequences of HPV-16 E7 in binding and competition assays to investigate whether these sequences can interact with additional ElA associated proteins.
The pRB-binding site of HPV-16 E7 has been mapped to the amino terminus of the viral protein. A peptide containing amino acids 2 to 32 of E7 that was homologous in length and composition with the ElA region 1+2 peptide was synthesized. The E7 peptide was first assayed for pRB-binding activity as previously described for ElA peptides (16) . E7 peptide, when coupled to Sepharose beads, bound to pRB polypeptides; both the level of binding and the pattern of polypeptides retained by the E7 peptide were identical to those seen with the ElA region 1+2 peptide (Fig. 7) . In competition assays, the E7 peptide was a more potent competitor of ElA association with pRB polypeptides in vitro than any of the ElA peptides were.
E7 peptide was added as a competitor to an in vitro binding reaction between ElA and labeled cellular proteins (Fig. 7B) . Both E7 and ElA peptides had similar effects on the binding reaction and inhibited ElA binding to pRB, p107, and p130. In this experiment it is also apparent that ElA binding to cyclin A was also significantly reduced in the presence of these peptides. Neither peptide had any effect on ElA association with p300, and no competition was seen with the control peptide. We investigated the specificity of the E7 peptide by coupling it to beads and incubating the beads in a labeled ceil lysate. A small number of proteins were specifically bound to beads carrying the E7;2-32 peptide (Fig. 8) . The most intense of these comigrated with proteins that bound to beads coupled with ElA peptide and were identified as pRB and p107 by two approaches. First, the products generated from these bands by partial digestion with S. aureus V8 protease were identical to those generated from the ElA-associated proteins (data not shown). Second, bead-associated proteins were separated by electrophoresis, transferred to nitrocellulose, and probed with monoclonal antibodies specific for pRB, p107, and cyclin A (Fig. 8C) . For these experiments two additional peptides, E7;2-20 and E7; [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] , that contained sequences homologous to pRBbinding regions 1 and 2 of EMA, respectively, were also tested to determine whether E7 contained two binding sites. Both E7 peptides that contained sequences homologous to region 2 of ElA (E7;2-32 and E7;16-32) bound to pRB. In contrast to the immunoblots of E7 immunoprecipitations, multiple forms of pRB were bound to the peptide beads. This suggests that although the E7 sequences have a preference for the unphosphorylated forms of pRB, they also can bind to the phosphorylated forms but with lower efficiency. In this the E7 peptide resembles the ElA region 1+2 peptide, which also bound the multiple forms of pRB (Fig. 5 ), but differs from the corresponding SV40 T-antigen peptide, which shows a strong preference for unphosphorylated pRB when coupled to Sepharose beads (data not shown).
E7 peptides that contained sequences homologous to region 2 of ElA (E7;2-32 and E7;16-32) also bound to p107
and to cyclin A. Two additional proteins of 45 and 32 kDa bound to the E7;2-32 peptide and were detected by the cyclin A antibody. These proteins were not seen with ElA peptides, and their significance is unclear. Surprisingly, beads coupled to the E7 region 1 peptide (E7;2-20) failed to bind to any of the ElA-associated proteins. This suggests that the amino terminus of E7 lacks binding sites analogous to ElA region 1. However, because this E7 peptide showed no significant activity in any of the assays described above, it is possible that the peptide fails to reproduce binding properties of the full-length protein. Nevertheless, these experiments show that the pRB-binding sequences of HPV-16 E7 are able to interact with a set of cellular proteins, comprising pRB, p107, p130, and cyclin A, that share overlapping binding sites on ElA. DISCUSSION Genetic studies reveal a tight correlation between the association of ElA with pRB and its transformation activities. Analysis of ElA mutants have suggested that the regions of ElA that are necessary for pRB binding are also important for association with additional cellular proteins, including p130, p107, cyclin A, and p33cdla. Using synthetic peptides to represent these regions of ElA, we have found that these short sequences are sufficient for stable association with pRB, p130, p107, and cyclin A. The binding of the cyclin A-associated protein p33cdl2 was not measured in these experiments but is likely to mirror the cyclin A binding pattern. In general, the properties of the synthetic peptides were consistent with the predictions of genetic studies and supported their conclusions. In several cases the peptidebinding properties revealed new pieces of information that complement the genetic analysis, and these results are summarized in Table 1 .
A new piece of information is the finding that peptides from two regions of ElA were sufficient for binding to p107. This result was unexpected since the analysis of ElA mutants has indicated that only amino acids 120 to 127 were essential for association with p107. However, in previous J. VIROL. ElA in vivo correlates with the failure to detect E2F-pRB and E2F-p1O7-cyclin A-cdk2 complexes, the appearance of unbound E2F, and an increase in transcription from E2F- dependent promoters (7, 31, 32, 44) . In similar experiments with HPV E7 proteins, GST-E7 fusion proteins were shown to dissociate the E2F-pRB complex in vitro, and the E2F-pRB complex was found to be reduced or absent in human cervical carcinoma cell lines in which E7 proteins were expressed (8) . In each of these studies, the effects of ElA and E7 were dependent on their pRB-binding sequences, leading to the suggestion that the ability of ElA and E7 proteins to dissociate E2F complexes is one function of these homologous sequences. Although E2F complexes may provide one target for these conserved elements, several lines of evidence indicate that these regions of ElA and E7 have more functions than simply the regulation of E2F. First, many cellular proteins bind to both pRB and p107 in vitro, and these interactions are inhibited by E7 and ElA peptides (21, 38) . Second, E7 and large T antigen have a reduced ability to dissociate E2F-p107 complexes, although both proteins bind to p107 with high affinity (8) . Third, as illustrated here, the pRB and p107 binding sequences also provide interaction with p130, a protein that has not been shown to associate with E2F.
